Insmed Inc

Insmed Inc Stock Forecast & Price Prediction

Live Insmed Inc Stock (INSM) Price
$29.21

6

Ratings

  • Buy 6
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$29.21

P/E Ratio

-7.47

Volume Traded Today

$1.0M

Dividend

Dividends not available for INSM

52 Week High/low

32.00/16.04

Insmed Inc Market Cap

$4.22B

🛑 Alert: These ten stocks could have higher potential than $INSM 🛑

Before you buy INSM you’ll want to see this list of ten stocks that have huge potential. Want to see if INSM made the cut? Enter your email below

INSM Summary

The Insmed Inc (INSM) share price is expected to increase by 42.07% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered INSM. Price targets range from $35.00 at the low end to $55.00 at the high end. The current analyst consensus for INSM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

INSM Analyst Ratings

Insmed Inc has a total of 6 Wall St Analyst ratings. There are 6 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Insmed Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

INSM stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

joseph schwartz
Leerink Partners

Buy

$50.0

reiterated

Feb 11, 2024
tiago fauth
Wells Fargo

Buy

$55.0

maintained

Feb 1, 2024
graig suvannavejh
Mizuho Securities

Buy

$35.0

reiterated

Jan 16, 2024
ritu baral
TD Cowen

Buy

$45.004

maintained

Jan 8, 2024
jeffrey hung
Morgan Stanley

Buy

$40.0

maintained

Jan 5, 2024
jason zemansky
Bank of America Securities

Buy

$37.0

reiterated

Jan 5, 2024
leon wang
Barclays

Buy

$37.0

maintained

Jan 5, 2024
jessica fye
J.P. Morgan

Buy

$36.0

initiatedcoverage

Nov 20, 2023
andrew fein
H.C. Wainwright

Buy

$52.0

reiterated

Oct 27, 2023
jennifer kim
Cantor Fitzgerald

Buy

$54.0

reiterated

Oct 26, 2023
liisa bayko
Evercore ISI

Buy

$42.0

maintained

Sep 7, 2023
vamil divan
Guggenheim

Buy

$52.0

maintained

Sep 5, 2023
stephen willey
Stifel Nicolaus

Buy

$35.0

maintained

Aug 4, 2023
judah frommer
Credit Suisse

Buy

$46.0

reiterated

Feb 24, 2023
andrea tan
Goldman Sachs

Buy

$39.0

maintained

Jan 9, 2023
carter gould
Barclays

Buy

$37.0

initiatedcoverage

Dec 7, 2022
matthew harrison
Morgan Stanley

Buy

$41.0

maintained

Jul 15, 2022
anita dushyanth
Berenberg Bank

Buy

$46.0

maintained

May 7, 2022
adam walsh
Stifel Nicolaus

Buy

$45.0

maintained

Mar 17, 2020
liav abraham
Citigroup

Hold

$30.0

maintained

Apr 3, 2019

INSM Company Information

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

INSM
Insmed Inc (INSM)

When did it IPO

N/A

Staff Count

736

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. William H. Lewis J.D., M.B.A.

Market Cap

$4.22B

Insmed Inc (INSM) Financial Data

In 2023, INSM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that INSM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $280.8M
  • Operating Margin TTM -175.4%
  • Gross profit TTM $190.2M
  • Return on assets TTM -36.2%
  • Return on equity TTM -547.5%
  • Profit Margin -257.7%
  • Book Value Per Share -2.02%
  • Market capitalisation $4.22B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-5.29

Insmed Inc (INSM) Latest News

... ...

Similar Stocks to Insmed Inc - INSM

🛑 Alert: These ten stocks could have higher potential than $INSM 🛑

Before you buy INSM you’ll want to see this list of ten stocks that have huge potential. Want to see if INSM made the cut? Enter your email below

...

INSM Frequently asked questions

The highest forecasted price for INSM is $55.00 from tiago fauth at Wells Fargo.

The lowest forecasted price for INSM is $35.00 from dana flanders from Guggenheim

The INSM analyst ratings consensus are 6 buy ratings, 0 hold ratings, and 0 sell ratings.